Difference between revisions of "Busulfan (Myleran)"
Jump to navigation
Jump to search
Warner-admin (talk | contribs) m (Text replacement - "Category:Intravenous chemotherapy" to "Category:Intravenous medications") |
Warner-admin (talk | contribs) m (Text replacement - "[[Bone cancer" to "[[Bone sarcoma") |
||
| Line 10: | Line 10: | ||
==Diseases for which it is used== | ==Diseases for which it is used== | ||
*[[Acute promyelocytic leukemia]] | *[[Acute promyelocytic leukemia]] | ||
| − | *[[Bone | + | *[[Bone sarcoma]] |
*[[CNS lymphoma]] | *[[CNS lymphoma]] | ||
*[[Transplant conditioning regimens]] | *[[Transplant conditioning regimens]] | ||
Revision as of 02:51, 24 October 2017
Also known as Busulfex.
General information
Class/mechanism: Bifunctional alkylating agent which produces guanine-adenine intrastrand crosslinks, inducing apoptosis.[1][2]
Route: IV
Extravasation: irritant
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, Medscape,UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Diseases for which it is used
Patient drug information
- Busulfan (Myleran) patient drug information (Chemocare)[3]
- Busulfan (Myleran) patient drug information (UpToDate)[4]
History of changes in FDA indication
- 6/26/1954: Initial FDA approval